Literature DB >> 26278799

A Step toward an Optimized Rifampin Dose Completed.

Martin J Boeree1,2, Andreas H Diacon3,4, Rodney Dawson5,6, Kim Narunsky5,6, Jeannine du Bois4, Amour Venter3, Patrick P J Phillips7, Stephen H Gillespie8, Timothy D McHugh9, Michael Hoelscher10,11, Norbert Heinrich10,11, Sunita Rehal7, Dick van Soolingen1,12, Jakko van Ingen1, Cecile Magis-Escurra1, David Burger1, Georgette Plemper van Balen1, Rob E Aarnoutse1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26278799     DOI： 10.1164/rccm.201506-1061LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  2 in total

1.  Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.

Authors:  C A Peloquin; G E Velásquez; L Lecca; R I Calderón; J Coit; M Milstein; E Osso; J Jimenez; K Tintaya; E Sanchez Garavito; D Vargas Vasquez; C D Mitnick; G Davies
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

2.  Rapid Microarray-Based Detection of Rifampin, Isoniazid, and Fluoroquinolone Resistance in Mycobacterium tuberculosis by Use of a Single Cartridge.

Authors:  Matthias Merker; Ines Labugger; Juliane Havlicek; Beatrice Dachsel; Peter Slickers; Sönke Andres; Patrick Beckert; Silke Feuerriegel; Stefan Niemann
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.